Zoetis Inc. (ZTS) is a global leader in the discovery, development, manufacture and commercialization of animal health medicines and vaccines. The Florham Park, NJ-based company focuses on both livestock and companion animals. The company came into existence following Pfizer’s decision to spin off its animal health business in 2013.
The company’s livestock products continue to do well and performance of companion animal products also improved during the quarter. Foreign exchange translations had a negative impact on revenues. Investor focus remains on updates on 2015 guidance.
Zoetis has an impressive earnings track record with the company delivering positive earnings surprises in three of the last four quarters with an average surprise of 3.45%.
Currently, Zoetis has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Zoetis beat on earnings by 4 cents. Our consensus called for EPS of 36 cents, and the company reported EPS of 40 cents.
Revenue: Revenues also surpassed expectations. Zoetis posted revenues of $1.32 billion, compared to our consensus estimate of $1.26 billion.
Key Stats: Once again, Zoetis has beaten our estimates driven primarily by total livestock revenue growth and improvement in companion animal products. For 2015, excluding one-time items, earnings are expected to be in the range of $1.61 to $1.68 per share. The company expects revenues to be between $4.8 billion and $4.9 billion.
Comments
Log in or sign up to join the conversation.